GAITHERSBURG, Md.–(BUSINESS WIRE)–Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration focuses on delivering transformative treatments for patients with Facioscapulohumeral Muscular Dystrophy (FSHD).
Building upon the companies’ successful partnership in developing ARC therapies, the expanded agreement will facilitate the advancement of a best-in-class ARC aimed at suppressing DUX4, the genetic driver of this debilitating muscular disease.
Sanofi will continue to contribute its expertise in rare disease drug development and will remain responsible for downstream clinical development and global commercialization.
Dr. Anthony Saleh, CEO of Mirecule, stated, “The expanded collaboration allows us to bring forward the optimal disease-modifying therapy for clinical advancement that meets the preclinical milestones established at the beginning of our partnership.”
Mirecule is strongly committed to developing a treatment for FSHD, working closely with the patient community. The company looks forward to ongoing collaboration with the FSHD Society, Friends of FSH Research, and the NINDS SBIR program to bring its groundbreaking FSHD treatment to fruition.
See the story on Businesswire:
https://www.businesswire.com/news/home/20260317767824/en/Mirecule-Expands-Strategic-FSHD-Collaboration-with-Sanofi